Pd Rx Pharmaceutical Stock Performance
| PDRX Stock | USD 2.90 0.00 0.00% |
Pd-Rx Pharmaceutical has a performance score of 2 on a scale of 0 to 100. The company owns a Beta (Systematic Risk) of 0.15, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pd-Rx Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pd-Rx Pharmaceutical is expected to be smaller as well. Pd Rx Pharmaceutical at this time owns a risk of 0.99%. Please check Pd Rx Pharmaceutical risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and day median price , to decide if Pd Rx Pharmaceutical will be following its current price history.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pd Rx Pharmaceutical are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Pd-Rx Pharmaceutical is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Pd-Rx |
Pd-Rx Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 285.00 in Pd Rx Pharmaceutical on October 3, 2025 and sell it today you would earn a total of 5.00 from holding Pd Rx Pharmaceutical or generate 1.75% return on investment over 90 days. Pd Rx Pharmaceutical is currently generating 0.0323% in daily expected returns and assumes 0.985% risk (volatility on return distribution) over the 90 days horizon. In different words, 8% of pink sheets are less volatile than Pd-Rx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pd-Rx Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pd-Rx Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pd Rx Pharmaceutical, and traders can use it to determine the average amount a Pd-Rx Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0328
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PDRX |
Based on monthly moving average Pd-Rx Pharmaceutical is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pd-Rx Pharmaceutical by adding it to a well-diversified portfolio.
Pd-Rx Pharmaceutical Fundamentals Growth
Pd-Rx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pd-Rx Pharmaceutical, and Pd-Rx Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pd-Rx Pink Sheet performance.
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0556 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 4.45 M | |||
| Shares Outstanding | 1.72 M | |||
| Price To Earning | 3.33 X | |||
| Price To Sales | 0.40 X | |||
| Revenue | 21.6 M | |||
| EBITDA | 991.1 K | |||
| Cash And Equivalents | 104.55 K | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 466.84 K | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 4.95 X | |||
| Cash Flow From Operations | (465.77 K) | |||
| Earnings Per Share | 1.08 X | |||
About Pd-Rx Pharmaceutical Performance
Evaluating Pd-Rx Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pd-Rx Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pd-Rx Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is headquartered in Oklahoma City, Oklahoma. Pd-Rx Pharmaceutical operates under Medical Distribution classification in the United States and is traded on OTC Exchange.Things to note about Pd Rx Pharmaceutical performance evaluation
Checking the ongoing alerts about Pd-Rx Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pd Rx Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pd Rx Pharmaceutical currently holds about 104.55 K in cash with (465.77 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. |
- Analyzing Pd-Rx Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pd-Rx Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Pd-Rx Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pd-Rx Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pd-Rx Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pd-Rx Pharmaceutical's pink sheet. These opinions can provide insight into Pd-Rx Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pd-Rx Pink Sheet Analysis
When running Pd-Rx Pharmaceutical's price analysis, check to measure Pd-Rx Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pd-Rx Pharmaceutical is operating at the current time. Most of Pd-Rx Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Pd-Rx Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pd-Rx Pharmaceutical's price. Additionally, you may evaluate how the addition of Pd-Rx Pharmaceutical to your portfolios can decrease your overall portfolio volatility.